[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-355998-105":59,"doc-detail-355998-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","prevalence-and-clinico-morphological-correlates-of-stk11-mutations-in-a-large-cohort-of-nsclc-lung-adenocarcinomas","Prevalence and clinico-morphological correlates of STK11 mutations in a large cohort of NSCLC lung adenocarcinomas","","STK11-mutated non-small cell lung cancers (NSCLC) are characterized by distinct clinicopathologic features, often alongside co-occurring KRAS and TP53 mutations that promote more aggressive disease. This retrospective study evaluated a large cohort of 1,068 primary lung cancer cases from 2018–2022, identifying 14 STK11-mutant lung adenocarcinomas. Clinicopathologic variables and demographics were collected, genomic profiling assessed co-mutations, and immunohistochemistry characterized associated phenotypes. STK11-mutant tumors occurred mainly in male smokers (median age 67), with KRAS or TP53 co-mutations in 50%. KRAS co-mutation increased metastasis, TP53 co-mutation increased necrosis and mitotic activity, and early-stage patients showed longer survival. PD-1/PD-L1 inhibitor (Pembrolizumab) therapy offered limited benefit, underscoring aggressive behavior and poor immunotherapy responsiveness. The study supports comprehensive genomic profiling to refine tumor biology and guide potential therapeutic decisions, while larger validations are needed.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/prevalence-and-clinico-morphological-correlates-of-stk11-mutations-in-a-large-cohort-of-nsclc-lung-adenocarcinomas/355998/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/prevalence-and-clinico-morphological-correlates-of-stk11-mutations-in-a-large-cohort-of-nsclc-lung-adenocarcinomas/355998.png","ImageObject",300,407,{"name":92,"@type":93},"Anna Hans","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-25","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":34},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"How was the study conducted to assess STK11-mutated NSCLC?","Question",{"text":112,"@type":113},"The study retrospectively reviewed 1,068 primary lung cancer cases from 2018 to 2022, including only those with confirmed STK11 mutations. It combined clinicopathologic data collection, genomic profiling for co-mutations, and immunohistochemistry to assess phenotypes.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What co-mutations were commonly observed with STK11, and what were their clinical effects?",{"text":117,"@type":113},"KRAS or TP53 co-mutations appeared in 50% of cases. STK11/KRAS tumors showed higher metastatic rates, while STK11/TP53 tumors had increased necrosis and mitotic activity.",{"name":119,"@type":110,"acceptedAnswer":120},"How did immunotherapy with PD-1/PD-L1 inhibitors perform in STK11-mutant patients?",{"text":121,"@type":113},"Patients treated with PD-1/PD-L1 inhibitors (Pembrolizumab) had limited benefit, with a median overall survival of 4.1 ± 2.8 months. The findings indicate poor responsiveness to current immunotherapies.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},355998,1790154475,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":34,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},5909892332657,"https://ap-avatar.wpscdn.com/davatar_994ba38a5ba835b3df7d355c54d3ed8d","Virchows Archiv (2026) 489:65–77  \n[https://doi.org/10.1007/s00428-025-04392-z](https://doi.org/10.1007/s00428-025-04392-z)  \nPrevalence and clinico‑morphological correlates of STK11 mutations in a large cohort of NSCLC lung adenocarcinomas  \nRizvan Rustamov1,2 · László Füzesi3 · Thomas Lesser4 · DagmarTäuscher5 · Uwe Funke6 · Peter Elsner7 · Masoud Mireskandari1 · Glen Kristiansen8 · Iver Petersen1  \nReceived: 11 July 2025 / Revised: 20 December 2025 / Accepted: 27 December 2025 / Published online: 19 January 2026 © The Author(s) 2026  \nAbstract  \nSTK11-mutated non–small cell lung cancers (NSCLC) show distinct clinicopathologic features, often with co-occurring KRAS and TP53 mutations that drive more aggressive disease. This study investigates the mutational landscape and clinical characteristics of STK11-mutated lung adenocarcinomas. We retrospectively reviewed 1,068 primary lung cancer cases from 2018 to 2022, identifying 14 STK11-mutant lung adenocarcinomas. We collected clinicopathologic data (demographics, histology, treatment), performed genomic profiling for co-mutations, and used immunohistochemistry to evaluate associated phenotypes. Patients with STK11 mutations (median age 67) were predominantly male smokers. KRAS or TP53 co-mutations appeared in 50% of cases. STK11/KRAS tumors showed higher metastatic rates, while STK11/TP53 tumors had increased necrosis and mitotic activity. Early-stage patients had longer survival, whereas advanced-stage cases faced significantly worse. Those treated with PD-1/PD-L1 inhibitors (Pembrolizumab) had limited benefit, with a median overall survival of 4.1 ± 2.8 months. STK11-mutant NSCLCs—especially with KRAS or TP53 co-mutations—demonstrate aggressive behavior and poor response to current immunotherapies. Comprehensive genomic profiling may help refine understanding of tumour biology and potentially inform treatment decisions. Larger studies are needed to validate these findings, but integrating genomic, pathologic, and clinical data may advance personalized therapy for these patients.  \nKeywords STK11/LKB1 · NSCLC · KRAS · TP53 · Genomic profiling · Metastasis · Immunotherapy resistance · Clinicopathological features  \nIntroduction  \nThe tumour suppressor gene STK11 (LKB1) encodes a serine/threonine kinase that plays a central role in regulating cellular metabolism, growth, and apoptosis. Acting upstream  \nDeceased. Dr. Petersen contributed substantially to the conception and initial drafting of this manuscript. This work is published in his memory.  \n* Glen Kristiansen [glen.kristiansen@ukbonn.de](glen.kristiansen@ukbonn.de)  \n1 Institute of Pathology, SRH Poliklinik Gera GmbH, Gera, Germany  \n2 University Hospital Jena, Jena, Germany  \n3 Pathology, Medical Faculty, University of Augsburg, Augsburg, Germany  \n4 Thoracic and Vascular Surgery, SRH Wald Klinikum, Gera, Germany  \nof AMPK, STK11 maintains energy homeostasis by inhibiting mTOR-driven anabolic processes; its loss disrupts this balance, promoting unchecked cell growth under metabolic stress [1–3] . Moreover, STK11 inactivation facilitates a metabolic shift toward glycolysis and biosynthetic pathways—hallmarks of cancer cell reprogramming [4 , 5] . Beyond metabolic effects, loss of STK11 contributes to an immunosuppressive tumor microenvironment. STK11-mutant  \n5 Pneumonology/Oncology, SRH Wald Klinikum, Gera, Germany  \n6 Regional Registry Unit at the Tumor Center, SRH Wald Klinikum, Gera, Germany  \n7 Department of Dermatology and Allergology, SRH Wald-Klinikum, Gera, Germany  \n8 Institute of Pathology, University Hospital Bonn (UKB), Venusberg-Campus 1, 53,127 Bonn, Germany  \ntumours typically exhibit low PD-L1 expression, poor CD8⁺ T-cell infiltration, and elevated pro-angiogenic and immunosuppressive cytokines, impairing responsiveness to immune checkpoint inhibitors like PD-1/PD-L1 antagonists [1, 6–8] .  \nWithin lung adenocarcinoma, STK11 mutations occur in roughly 20–30% of cases and often co-occur with KRAS or TP53 ","cbCaij76h6xa8UOb","https://ap.wps.com/l/cbCaij76h6xa8UOb","pdf",1953668,13,"English","# Abstract\n## Study design and cohort\n## Key clinical and molecular findings\n## Survival and immunotherapy outcomes\n## Conclusions and implications\n# Introduction\n## STK11 function and tumor metabolism\n## STK11 and immune microenvironment\n## Co-mutations with KRAS/TP53\n## Rationale for integrated molecular and clinicopathologic characterization\n# Materials and methods\n## Patients and samples\n## Histopathological evaluation","[{\"question\":\"How was the study conducted to assess STK11-mutated NSCLC?\",\"answer\":\"The study retrospectively reviewed 1,068 primary lung cancer cases from 2018 to 2022, including only those with confirmed STK11 mutations. It combined clinicopathologic data collection, genomic profiling for co-mutations, and immunohistochemistry to assess phenotypes.\"},{\"question\":\"What co-mutations were commonly observed with STK11, and what were their clinical effects?\",\"answer\":\"KRAS or TP53 co-mutations appeared in 50% of cases. STK11/KRAS tumors showed higher metastatic rates, while STK11/TP53 tumors had increased necrosis and mitotic activity.\"},{\"question\":\"How did immunotherapy with PD-1/PD-L1 inhibitors perform in STK11-mutant patients?\",\"answer\":\"Patients treated with PD-1/PD-L1 inhibitors (Pembrolizumab) had limited benefit, with a median overall survival of 4.1 ± 2.8 months. The findings indicate poor responsiveness to current immunotherapies.\"}]","Prevalence and clinico-morphological correlates of STK11 mutations in a large cohort of NSCLC lung adenocarcinomas | PDF",1790122222,33,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/4e01cf8b1485fedc0ccf41ccd8825193.webp",983,1305,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/d44d1ab1ee97671f1dd35f7d297578a4.webp",982,1304,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/03cabefee6b821836165e5c9340a6c04.webp",981,1303,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/57b1b070bf3fd8ce3afa8b4f70f21a3c.webp",980,1301]